What is the recommended treatment approach for eosinophilic esophagitis?

Treatment of Eosinophilic Esophagitis

First-line treatment for eosinophilic esophagitis should be either proton pump inhibitors (PPIs) twice daily, topical corticosteroids, or elimination diets—all are equally valid initial options with PPIs offering the simplest approach and topical steroids providing the highest remission rates.

Primary Treatment Options

The 2022 British Society of Gastroenterology guidelines establish three equally acceptable first-line therapies 1:

Proton Pump Inhibitors (Preferred Initial Approach)

• Dosing: Twice daily for 8-12 weeks before assessing histological response 1
• Efficacy: Moderate evidence for inducing histological and clinical remission (approximately 45% remission rate) 1, 2
• Advantages: Simplest to implement, well-tolerated, effective for maintenance therapy in responders 1
• Key point: Continue long-term in responders as maintenance therapy 1

Topical Corticosteroids (Highest Efficacy)

• Evidence quality: HIGH for inducing remission 1
• Efficacy: 80-93% histological remission rates 2
• Critical caveat: Relapse rates are high after withdrawal—maintenance treatment is mandatory 1
• Additional benefit: Reduces stricture development over time 1
• Approved formulations: Orodispersible budesonide (Jorveza® in Europe/Canada/Australia; Eohilia® in USA for ages ≥11 years) 3

Elimination Diets

• Efficacy: Moderate evidence, approximately 60% remission 1, 2
• Six-food elimination diet: Highest remission rates but lowest compliance and requires multiple endoscopies 1
• Essential requirement: Experienced dietitian support throughout elimination and reintroduction phases 1
• Important: Allergy testing (skin prick, IgE, patch testing) is NOT recommended for selecting foods to eliminate 1

Treatment Algorithm

Step 1: Initial Therapy Selection

• Choose based on patient preference, compliance likelihood, and local expertise
• PPIs: Best for patients wanting simplest approach
• Topical steroids: Best for highest remission rates
• Diet: Best for patients preferring non-pharmacologic approach with dietitian access

Step 2: Assessment at 8-12 Weeks

• Mandatory endoscopy with biopsy while on treatment to assess histological response 1
• Symptoms alone do NOT correlate reliably with histological activity 1
• Target: <15 eosinophils per 0.3 mm² 1

Step 3: Responders

• Continue maintenance therapy indefinitely 1
• Do NOT stop treatment—relapse rates are extremely high 1

Step 4: Non-responders or Treatment Failure

• Switch to alternative first-line therapy
• Consider combining diet with pharmacotherapy (though not routinely recommended) 1
• Reserve elemental diets for refractory cases only—high efficacy but very poor compliance 1

Advanced Therapies

Dupilumab (Biologic)

• FDA/EMA approved for EoE in patients ≥12 years (Europe) or ≥1 year and ≥15 kg (USA) 3, 4
• Indication: Unresponsive, intolerant, or not candidates for conventional therapies 3
• Efficacy: Approximately 60% remission 2
• Represents first approved biologic for EoE 5, 3

Refractory Disease Management

• Joint management with gastroenterologist AND allergist 1
• Novel biologics (cendakimab, benralizumab) show promise but remain investigational 1

Management of Fibrostenotic Disease

Endoscopic dilation is safe and effective for strictures but does NOT treat underlying inflammation 1, 6:

• Perforation rate: 0.4% (improved significantly post-2009 with conservative approach) 6
• Can use balloon or bougie dilators 1
• Critical: Must combine with anti-inflammatory therapy (topical steroids preferred) for optimal outcomes 1
• Maintenance topical steroids reduce recurrent food bolus obstruction risk 1

What NOT to Use

The following have strong recommendations AGAINST use 1:

• Immunomodulators (azathioprine, 6-mercaptopurine)
• Anti-TNF therapies (infliximab)
• Anti-integrin therapies (vedolizumab)
• Sodium cromoglycate, montelukast, antihistamines (unless for concomitant atopic disease)

Monitoring Strategy

• If symptoms recur on treatment: Repeat endoscopy with histology immediately 1
• Long-term: Periodic endoscopic surveillance to prevent fibrostenotic progression
• Untreated disease: Approximately 5% annual stricture risk 2
• Early diagnosis and treatment may prevent fibrosis and strictures 1, 6

Common Pitfalls

1. Stopping treatment after initial response—relapse is nearly universal 1
2. Relying on symptoms alone—histological activity persists despite symptom improvement 1
3. Using allergy testing to guide dietary elimination—not evidence-based 1
4. Aggressive dilation without anti-inflammatory therapy—suboptimal outcomes 1
5. Withdrawing PPIs before diagnostic endoscopy—wait at least 3 weeks if EoE suspected 1